Current IBD therapies, based on decreasing signs and symptoms, do not eliminate the disease, cause frequent side effects, are expensive and inefficient in many patients, and cause immunosuppression, like anti-TNFα drugs. This evidence concerns the gene TNF and inflammatory bowel disease.